KVKVISITFBETAG-ZHRRRDCSSA-N
Compound with spectra: 1 NMR
| SpectraBase Compound ID | CeSzLA4EjUh |
|---|---|
| InChI | InChI=1S/C44H62N12O11S2/c1-25-38(61)54-32(21-35(45)58)41(64)55-33(43(66)56-17-6-10-34(56)42(65)53-30(9-5-16-49-44(47)48)39(62)50-22-36(46)59)24-69-68-18-15-37(60)52-31(20-27-11-13-29(57)14-12-27)40(63)51-28(23-67-25)19-26-7-3-2-4-8-26/h2-4,7-8,11-14,25,28,30-34,57H,5-6,9-10,15-24H2,1H3,(H2,45,58)(H2,46,59)(H,50,62)(H,51,63)(H,52,60)(H,53,65)(H,54,61)(H,55,64)(H4,47,48,49)/t25-,28-,30+,31-,32+,33+,34+/m0/s1 |
| InChIKey | KVKVISITFBETAG-ZHRRRDCSSA-N |
| Mol Weight | 999.2 g/mol |
| Molecular Formula | C44H62N12O11S2 |
| Exact Mass | 998.410243 g/mol |
| Enantiomer InChIKey | KVKVISITFBETAG-YDQBQXGVSA-N |
| Copyright | Copyright © 2016-2024 W. Robien, Inst. of Org. Chem., Univ. of Vienna. All Rights Reserved. |
|---|---|
| Solvent | H2O:D2O=9:1 |
1-[19-amino-7-(2-amino-2-keto-ethyl)-10-(3-amino-3-keto-propyl)-16-(4-hydroxybenzyl)-6,9,12,15,18-pentaketo-13-sec-butyl-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carbonyl]-N-[1-[(2-amino-2-keto-ethyl)carbamoyl]-3-methyl-butyl]pyrrolidine-2-carboxamid
Aspartocin
(4-Leucine)-ocytocin
Mesotocin
(2-Phenylalanine-4-leucine)-ocytocin
Isotocin
PHAKELLISTATIN_16;CYCLO-(PRO-PHE-ASP-SER-ARG-ALA-VAL-THR-TYR);MAJOR_ISOMER
(2-Leucine-3-proline-4-[.alpha.,.alpha.-dideuterio-glycine])-ocytocin
GOMBAMIDE_A
L-N^2-{N-{1-{N-{N-{N-[1-(1-L-ARGINYL-L-PROLYL)-L-PROLYL]GLYCYL}-3-PHENYL-L-ALANYL}-L-SERYL}-L-PROLYL}-3-PHENYL-L-ALANYL}ARGININE, DIACETATE (SALT), TRIHYDRATE
| Title | Journal or Book | Year |
|---|---|---|
| Conformations and Receptor Activity of Desmopressin Analogues, Which Contain γ-Turn Mimetics or a Ψ[CH2O] Isostere | Journal of Medicinal Chemistry | 2002 |
This compound is available in the following databases:
KnowItAll NMR Spectral Library
Author: Wiley
The KnowItAll NMR Spectral Library offers a comprehensive collection of NMR reference spectra, including NMR, CNMR, and XNMR, and covers a wide range of compounds including organics, polymers, monomers, metabolites, and more. Learn more.